



(51) International Patent Classification:
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/EP2010/059024

(22) International Filing Date:
24 June 2010 (24.06.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/220,358 25 June 2009 (25.06.2009) US
61/239,880 4 September 2009 (04.09.2009) US
61/322,102 8 April 2010 (08.04.2010) US

(71) Applicant (for all designated States except US): **GLAXO-SMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAUDOUX, Guy Jean Marie Fernand Pierre** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **COLAU, Brigitte Desiree Alberte** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **DENDOUGA, Najoua** [FR/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **GIANNINI, Sandra** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **LECRENIER, Nicolas Pierre Fernand** [BE/BE]; GlaxoSmithKline Biologicals s.a., Parc de la Noire Epine, rue Fleming 20, B-1300 Wavre (BE).

(74) Agents: **DALTON, Marcus Jonathan William** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: NOVEL COMPOSITIONS

(57) Abstract: The disclosure provides novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease. The constructs are chimeric proteins comprising L1 proteins with an HPV L2 peptide inserted in to the L1 protein. Such chimeric proteins may be formulated into immunogenic e.g. vaccine compositions, and optionally formulated with HPV L1 VLP based vaccines.

